Norris Medicines Ltd Appoints Iqubal Ismail Patel as Chief Financial Officer and KMP
Norris Medicines Ltd has appointed Mr. Iqubal Ismail Patel as the Company's Chief Financial Officer (CFO) and Key Managerial Personnel (KMP). The appointment was finalized by the Board of Directors in a meeting held on July 30, 2026, following recommendations from the Audit Committee and the Nomination and Remuneration Committee.Mr. Patel’s appointment is effective immediately as of July 30, 2026. His tenure terms are set to be mutually agreed upon with the Board of Directors, covering all terms and conditions including remuneration.
CFO Appointment Details
Mr. Iqubal Ismail Patel brings extensive experience to his role at Norris Medicines Ltd. He has been associated with the company for over 11 years, leveraging rich expertise in finance, accounts, taxation, budgeting, financial planning, and corporate management. Additionally, he holds a Graduate degree.The details regarding the appointment are summarized below:
| Detail | Information |
|---|---|
| Name of CFO | Mr. Iqubal Ismail Patel |
| Reason for Change | Appointment as Chief Financial Officer of the Company |
| Date of Appointment | July 30, 2026 |
| Term of Appointment | Determined by mutual agreement between Mr. Iqubal Ismail Patel and the Board of Directors regarding terms and conditions including remuneration |
| Profile Summary | Associated with Norris Medicines Ltd for more than 11 years, possessing rich experience in finance, accounts, taxation, budgeting, financial planning, and corporate management. Holds a Graduate degree. |
| Director Relationship | He is not related to any of the Directors or Key Managerial Personnel of the Company |
The appointment affirms the company's commitment to strengthening its financial leadership through experienced internal talent.
Stock Price Movement
Norris Medicines Ltd shares tumbled on Thursday post-market, settling at ₹14.82, representing a 2.05% decline. Throughout the trading session, the shares fluctuated within an intraday range of ₹14.82 to ₹15.13.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.